Myelin is a vital part of the nervous system, acting as a protective coating for nerve fibers and facilitating signal transmission between them. When the immune system mistakenly attacks myelin, a process known as demyelination occurs, which can lead to nerve dysfunction and the emergence of various symptoms in multiple sclerosis patients.
The importance of this experimental treatment lies in its direct targeting of myelin, noting that currently available therapies focus largely on reducing immune system activity and disease-related inflammation, while not necessarily being able to restore damaged myelin.
According to the developer, Lucid-MS works by inhibiting a group of enzymes believed to cause changes in myelin proteins, making them more susceptible to autoimmune attacks. By influencing this process, researchers hope the treatment will contribute to limiting further myelin loss and supporting repair processes.
Preclinical studies conducted on animal models showed encouraging results, indicating the treatment's ability to limit myelin loss and promote its restoration, alongside improvements in some symptoms and motor functions in the animals studied. The treatment also underwent a phase 1 clinical trial involving healthy adults, where it was considered safe and well-tolerated according to the company.
One researcher notes that progressive multiple sclerosis remains a major challenge for patients and physicians due to limited effective treatment options, expressing the belief that targeting myelin integrity rather than suppressing the immune system could provide a different therapeutic approach.
The phase 2 study is scheduled to be randomized, double-blind, and placebo-controlled, with the aim of evaluating the efficacy of Lucid-MS using clinical and radiological indicators associated with disability progression, in addition to assessing its safety and tolerability.
The company has already begun the necessary preparations for the trials, including selecting study sites, with patient enrollment and dosing expected to begin as soon as possible.
However, Lucid-MS remains an experimental treatment, and at this stage, it cannot be definitively stated that it can stop the progression of multiple sclerosis or repair neurological damage in patients, as the results of clinical trials will determine its efficacy, safety, and the possibility of moving to subsequent stages of development and regulatory approval.
